Emerging Infections Program as Surveillance for Antimicrobial Drug Resistance - Volume 21, Number 9—September 2015 - Emerging Infectious Disease journal - CDC
Volume 21, Number 9—September 2015
Emerging Infections Program
Emerging Infections Program
Emerging Infections Program as Surveillance for Antimicrobial Drug Resistance
The 1992 Institute of Medicine report Emerging Infections: Microbial Threats to Health in the United States describes the ability of microbes to adapt, the development of antimicrobial drug resistance, and the importance of recognizing and monitoring emerging microbial threats to human health (1). In response, because of the recognized need for more accurate surveillance to detect and address emerging microbial health threats, in 1994 the Centers for Disease Control and Prevention (CDC) Emerging Infections Program (EIP) was established as a collaboration of CDC and state health departments and academic partners. EIP works collaboratively across different programs and disease areas at CDC to deliver critical data that the program is well suited to obtain (2).
Dr. Fridkin is a senior advisor for Antibiotic Resistance in Healthcare, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC. His work involves implementing and expanding surveillance and public health research of antimicrobial drug–resistant infections associated with health care delivery.
- Institute of Medicine (US) Committee on Emerging Microbial Threats to Health. In: Lederberg J, Shope RE, Oaks SC, editors. Emerging infections: microbial threats to health in the United States. Washington (DC): National Academies Press (US); 1992.
- Pinner RW, Lynfield R, Hadler JL, Schaffner W, Farley MM, Frank ME, Cultivation of an adaptive domestic network for surveillance and evaluation of emerging infections. Emerg Infect Dis. 2015; 21:1499–1509. DOI
- Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013 [cited 2015 Mar 3].http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf
- McCormick AW, Whitney CG, Farley MM, Lynfield R, Harrison LH, Bennett NM, Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med. 2003;9:424–30. DOIPubMed
- Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Effect of introduction of the pneumococcal conjugate vaccine on drug-resistantStreptococcus pneumoniae. N Engl J Med. 2006;354:1455–63. DOIPubMed
- Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2000;343:1917–24. DOIPubMed
- Woodbury RL, Klammer KA, Xiong Y, Bailiff T, Glennen A, Bartkus JM, Plasmid-borne erm(T) from invasive, macrolide-resistant Streptococcus pyogenes strains. Antimicrob Agents Chemother. 2008;52:1140–3. DOIPubMed
- Castor ML, Whitney CG, Como-Sabetti K, Facklam RR, Ferrieri P, Bartkus JM, Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol. 2008;2008:727505.
- Wu HM, Harcourt BH, Hatcher CP, Wei SC, Novak RT, Wang X, Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med. 2009;360:886-92. DOIPubMed
- Suggested citation for this article: Magill SS, Dumyati G, Ray SM, Fridkin SK. Evaluating the epidemiology and improving surveillance of healthcare-associated infections. Emerg Infect Dis. 2015;1537–1542. DOI
- Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clin Infect Dis. 2012;55:1352–61. DOIPubMed
- Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB, Species identification and antifungal susceptibility testing of Candidabloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol. 2012;50:3435–42.DOIPubMed
- Ahlquist AM, Harrison LH, Farley MM, Schaffner W, Beldavs Z, Iqbal N, The emergence of multidrug resistant Candida species: results from a population-based laboratory surveillance in the United States, 2008–2012. In: Abstracts of the 18th Congress of the International Society for Human and Animal Mycology; Berlin, Germany; 2012 Jun 11–15. Mycoses. 2012;55(Suppl 4):252. Abstract P500.
- Pham CD, Iqbal N, Bolden CB, Kuykendall RJ, Harrison LH, Farley MM, Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother. 2014;58:4690–6. DOIPubMed
- Chea N, Bulens SN, Kongphet-Tran T, Lynfield R, Shaw KM, Vagnone PS, Improved phenotype-based definition for identifying carbapenemase producers among carbapenem-resistant Enterobacteriaceae. Emerg Infect Dis. 2015;21:1611–6. DOI
- Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus—Minnesota and North Dakota, 1997–1999. MMWR Morb Mortal Wkly Rep. 1999;48:707–10 .PubMed
- Fridkin SK. Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352:1436–44.
- Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Invasive methicillin-resistant Staphylococcus aureus infections in the United States.JAMA. 2007;298:1763–71. DOIPubMed
- Dantes R, Mu Y, Belflower R, Aragon D, Dumyati G, Harrison LH, National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States. JAMA Intern Med. 2013;173:1970–8 .PubMed
- Centers for Disease Control and Prevention. National Antimicrobial Resistance Monitoring System for enteric bacteria (NARMS): human isolates final report, 2011. Atlanta: The Centers; 2013.
- Scallan E, Hoekstra RM, Angulo FJ. Tauxe RV, Widdowson MA, Roy SL, et al. Foodborne illness acquired in the United States—major pathogens. Emerg Infect Dis. 2011;17:7–15.
- Kassenborg HD, Smith KE, Vugia DJ, Rabatsky-Ehr T, Bates MR, Carter MA, Fluoroquinolone-resistant Campylobacter infections: eating poultry outside of the home and foreign travel are risk factors. Clin Infect Dis. 2004;38(Suppl 3):S279–84. DOIPubMed
- Nelson JM, Smith KE, Vugia DJ, Rabatsky-Ehr T, Segler SD, Kassenborg HD, Prolonged diarrhea due to ciprofloxacin-resistant Campylobacterinfection. J Infect Dis. 2004;190:1150–7. DOIPubMed
- Executive O-CA-RB. The White House. September 18, 2014 [cited 2014 Oct 28]. http://www.whitehouse.gov/the-press-office/2014/09/18/executive-order-combating-antibiotic-resistant-bacteria
Suggested citation for this article: Fridkin SK, Cleveland AA, See I, Lynfield R. Emerging Infections Program as surveillance for antimicrobial drug resistance. Emerg Infect Dis. 2015 Sep [date cited]. http://dx.doi.org/10.3201/eid2109.150512
No hay comentarios:
Publicar un comentario